# Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease

> **NCT04679883** · PHASE2 · UNKNOWN · sponsor: **GL Pharm Tech Corporation** · enrollment: 99 (estimated)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** 5% GLH8NDE
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04679883
- **Lead sponsor:** GL Pharm Tech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679883, "Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT04679883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*